DE60042026D1 - Virale replikons und von induzierenden wirkstoffen abhängige viren - Google Patents

Virale replikons und von induzierenden wirkstoffen abhängige viren

Info

Publication number
DE60042026D1
DE60042026D1 DE60042026T DE60042026T DE60042026D1 DE 60042026 D1 DE60042026 D1 DE 60042026D1 DE 60042026 T DE60042026 T DE 60042026T DE 60042026 T DE60042026 T DE 60042026T DE 60042026 D1 DE60042026 D1 DE 60042026D1
Authority
DE
Germany
Prior art keywords
replicon
gene
hiv1
rtta
ltrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60042026T
Other languages
English (en)
Inventor
Benjamin Berkhout
Koenraad Dirk Verhoef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Academisch Medisch Centrum
Original Assignee
Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Academisch Medisch Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Medisch Centrum Bij de Universiteit van Amsterdam, Academisch Medisch Centrum filed Critical Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Application granted granted Critical
Publication of DE60042026D1 publication Critical patent/DE60042026D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60042026T 1999-09-10 2000-09-08 Virale replikons und von induzierenden wirkstoffen abhängige viren Expired - Fee Related DE60042026D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202971A EP1083230A1 (de) 1999-09-10 1999-09-10 Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
PCT/NL2000/000637 WO2001020013A2 (en) 1999-09-10 2000-09-08 Viral replicons and viruses dependent on inducing agents

Publications (1)

Publication Number Publication Date
DE60042026D1 true DE60042026D1 (de) 2009-05-28

Family

ID=8240635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042026T Expired - Fee Related DE60042026D1 (de) 1999-09-10 2000-09-08 Virale replikons und von induzierenden wirkstoffen abhängige viren

Country Status (9)

Country Link
US (1) US20030099613A1 (de)
EP (2) EP1083230A1 (de)
JP (1) JP2003509059A (de)
AT (1) ATE428792T1 (de)
AU (1) AU780984B2 (de)
CA (1) CA2386530A1 (de)
DE (1) DE60042026D1 (de)
WO (1) WO2001020013A2 (de)
ZA (1) ZA200201923B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1479774A1 (de) * 2003-05-20 2004-11-24 Academisch Medisch Centrum Viren die induzierende Wirkstoffe für den Zelleintritt benötigen
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
AU2006316288B2 (en) * 2005-11-17 2012-12-20 Tet Systems Gmbh & Co. Kg Inducible expression systems
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
FI1974017T4 (fi) 2005-12-09 2023-09-14 Välineitä ja menetelmiä, joilla voidaan vaikuttaa vasta-ainetta tuottavien solujen stabiliteettiin
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
EP2319918B1 (de) * 2009-11-10 2013-01-16 Centre National De La Recherche Scientifique Vektor auf Lentivirus beruhend und dessen Verwendung bei der zielgerichteten Evolution von genomischen Regionen, Genen und Polynukleotiden
EP2646466B1 (de) 2010-12-02 2017-03-29 AIMM Therapeutics B.V. Mittel und methoden zur produktion von hoch affinen antikörpern
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
CN111521359A (zh) * 2020-04-29 2020-08-11 河南工程学院 面向结构振动主动控制优化配置方法及振动控制实验平台
CN118360259B (zh) * 2024-06-18 2024-09-27 苏州药明检测检验有限责任公司 一种条件复制型hiv弱毒株及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4100594A1 (de) * 1991-01-08 1992-07-09 Inst Genbiologische Forschung Neue plasmide zur zeitlichen und oertlichen kontrollierten expression eines heterologen produktes in pflanzen
PT584348E (pt) * 1992-03-11 2005-10-31 Powderject Vaccines Inc Vacina genetica para virus da imunodeficiencia
US5723765A (en) * 1994-08-01 1998-03-03 Delta And Pine Land Co. Control of plant gene expression
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US5965440A (en) * 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
AU3212197A (en) * 1996-06-20 1998-01-07 Salk Institute For Biological Studies, The Modular assembly retroviral vectors and uses thereof
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
WO2000037660A1 (en) * 1998-12-22 2000-06-29 Dow Agrosciences Llc Methods and genetic compositions to limit outcrossing and undesired gene flow in crop plants
MXPA02000969A (es) * 1999-07-28 2004-04-21 Smith Stephen Vacuna de virus de inmuno-deficiencia humana atenuado controlado en forma condicional.

Also Published As

Publication number Publication date
WO2001020013A3 (en) 2001-09-27
EP1212446A2 (de) 2002-06-12
JP2003509059A (ja) 2003-03-11
AU7459500A (en) 2001-04-17
ATE428792T1 (de) 2009-05-15
AU780984B2 (en) 2005-04-28
EP1083230A1 (de) 2001-03-14
US20030099613A1 (en) 2003-05-29
EP1212446B1 (de) 2009-04-15
ZA200201923B (en) 2003-09-23
CA2386530A1 (en) 2001-03-22
WO2001020013A2 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
DE60042026D1 (de) Virale replikons und von induzierenden wirkstoffen abhängige viren
ES2706899T3 (es) Vectores de terapia génica y citosina desaminasas
Das et al. The HIV-1 Tat protein has a versatile role in activating viral transcription
Hoffmann et al. Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells
DE69230882D1 (de) Cytosindeaminase negatives selektionssystem zur genübertragung und therapien
Carvajal et al. Structural domains within the HIV‐1 mRNA and the ribosomal protein S25 influence cap‐independent translation initiation
Bartholomeeusen et al. A chikungunya virus trans-replicase system reveals the importance of delayed nonstructural polyprotein processing for efficient replication complex formation in mosquito cells
DE69128077D1 (de) Nuklein-säure amplifikation mit dns abhängigen rns polymerasen aktivität von rns-replikasen
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
DK0935660T3 (da) Infektiöse kloner af RNA-virusser og vacciner og deraf afledte diagnostiske assays
DK0544894T3 (da) Anvendelse af exo-prøve-nukleotider i genkloning
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
DE3586520D1 (de) Herpes simplex-virus als vektor.
ES2194865T3 (es) Amplificacion viral de arn mensajero recombinante en plantas transgenicas.
Lello et al. nsP4 is a major determinant of alphavirus replicase activity and template selectivity
Qiao et al. Novel tag-and-exchange (RMCE) strategies generate master cell clones with predictable and stable transgene expression properties
Marzio et al. Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription
ATE292186T1 (de) Konditionell kontrollierter, attenuierter hiv-1 impfstoff
Lund et al. The kissing-loop motif is a preferred site of 5′ leader recombination during replication of SL3-3 murine leukemia viruses in mice
Das et al. Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication
van der Velden et al. Tat has a dual role in simian immunodeficiency virus transcription
Yoshida et al. HIV-1 RNAs whose transcription initiates from the third deoxyguanosine of GGG tract in the 5′ long terminal repeat serve as a dominant genome for efficient provirus DNA formation
DE69434830D1 (de) Zur verleihung viraler resistenz an pflanzen geeignetes polyribozym und dieses polyribozym produzierende resistente pflanzen
Stephens et al. Simian-human immunodeficiency virus (SHIV) containing the nef/long terminal repeat region of the highly virulent SIVsmmPBj14 causes PBj-like activation of cultured resting peripheral blood mononuclear cells, but the chimera showed No increase in virulence
Ebina et al. Perspectives of genome-editing technologies for HIV therapy

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee